Chao Deng Meng Yang Hong Jiang Renbin Wang Zhaojun Yang Hongliang Sun Huijuan Cui
10.3389/fonc.2021.664809
Front Oncol
2021 Sep 2;11:664809.
immune checkpoint inhibitors (icis) immune-related adverse events (iraes) non-small cell lung cancer (nsclc) programmed cell death-1(pd-1) tislelizumab
CC BY
https://pubmed.ncbi.nlm.nih.gov/34540659/
Case Reports
PMC8443792
34540659
Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report
2021